Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Galapagos

Biotech & Life Sciences · Mechelen, Belgium · Founded 1999 · IPO 2015 Unicorn

Clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines

Revenue
$1.22B
Latest reported FY
EBITDA
$665M
Latest reported FY

Investors

2 investors on Galapagos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Thuja Capital
Series B+ 1 investor entered at this stage
Gilde Healthcare

Global footprint

Where Galapagos has talent and traffic

AI talent share
1.1% of workforce is AI talent
(9 of 785 staff)
Core AI00%
Other AI91.15%
Non-AI workforce77698.85%
Workforce by country
🇧🇪 Belgium · Mechelen HQ
Book a demo for the full country breakdown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States21.7%
🇧🇪 Belgium15.7%
🇳🇱 Netherlands12.2%
🇬🇧 United Kingdom12.2%
🇮🇳 India7.8%
Top 5 markets shown

Patent intelligence

$230M patent portfolio · 103 active families

Estimated portfolio value
$230M
2.3× the top peer Celltrion ($101M)
103 active patent families
Where Galapagos innovates Pharmaceutical drugUreaCarbonyl groupHydrogenCombinatorial chemistry

Where Galapagos concentrates vs peers

Each axis is a top-10 topic across Galapagos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Galapagos's 7 investments and acquisitions.

Every disclosed deal where Galapagos appeared as a backer or acquirer, 2013–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

7 deals across Galapagos's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Galapagos's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        7 of 7 deals

        Market sentiment

        What the market is saying about Galapagos

        An AI-synthesized read of the highest-engagement posts about Galapagos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Galapagos on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.